The results revealed that either EPZ015666 or SP2509 resulted in the induction of E-cadherin and the reduction of vimentin, and strikingly the treatment of both EPZ015666 and SP2509 led to stronger changes than single inhibitor treatment in the expression of these two markers at both protein (Fig. 5A, B and Figure S5B) and mRNA (Fig. 5C, D and Figure S5B) levels in breast cancer cells. The gene discussed is CDH1; the disease is breast carcinoma.